A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)

Summary

This study will evaluate the lipid-modifying effect and tolerability of MK1903 when compared to placebo in patients with dyslipidemia who are not on a statin or other lipid-modifying therapy.

Timeline

Start

2008-06

Primary completion

2009-09

Completion

2009-09

Outcome

Mixed primary results

registry MK1903 vs Placebo; p = 0.926; Mean Difference (Final Values) 0.2 (95% CI -3.9 to 4.3) NCT00847197 ↗

registry MEAN MK1903: 6.0 (Standard Deviation 13.0) Percent Change NCT00847197 ↗

registry MK1903 vs Placebo; p = 0.013; Mean Difference (Final Values) 4.6 (95% CI 1.0 to 8.1) NCT00847197 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK1903	Unknown	150 mg	Oral

Indications